Caxton Associates (New York)’s Vanda Pharmaceuticals VNDA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-192,884
| Closed | -$833K | – | 548 |
|
|
2023
Q3 | $833K | Buy |
192,884
+151,344
| +364% | +$654K | 0.11% | 178 |
|
|
2023
Q2 | $274K | Sell |
41,540
-111,844
| -73% | -$737K | 0.04% | 357 |
|
|
2023
Q1 | $1.04M | Buy |
153,384
+23,759
| +18% | +$161K | 0.16% | 132 |
|
|
2022
Q4 | $958K | Buy |
129,625
+14,274
| +12% | +$105K | 0.06% | 106 |
|
|
2022
Q3 | $1.14M | Buy |
115,351
+3,001
| +3% | +$29.7K | 0.15% | 77 |
|
|
2022
Q2 | $1.23M | Buy |
112,350
+71,049
| +172% | +$775K | 0.12% | 71 |
|
|
2022
Q1 | $467K | Buy |
+41,301
| New | +$467K | 0.04% | 246 |
|